Aspartame and Platelets in Type II Diabetic Patients


  •   Arbind Kumar Choudhary


Background: For type II diabetes (T2D) subjects to better regulate carbohydrate consumption and manage blood glucose levels, a non-nutritive sweetener (aspartame) is prescribed as an alternative to natural sugar. Previous studies show that there was a 68% rise in the probability of aspartame consumers developing T2D compared with non-consumers. In diabetes and inflammation, deformed red blood cells (RBCs) and atypical fibrin fibre formation or an altered fibrin structure are especially prevalent.

Objective: The aim of this study was to investigate, in subjects with T2D taking aspartame, clot viscoelasticity and platelet structure.

Methodology: Blood was drawn from 12 T2D subjects from the diabetic clinic at the Steve Biko Academic Hospital, South Africa. Blood was used to perform a full blood count, thromboelastography (TEG) and scanning electron microscopy (SEM).

Results: SEM showed increased platelet activation and abnormal TEG parameters in T2D consuming aspartame.

Conclusion: A hypercoagulable state can increase the risk of thromboembolic complications and an increased incidence of vascular disease. This knowledge may be used to build awareness among consumers of aspartame.

Keywords: Aspartame, blood, coagulation, diabetes, platelets


Roberts HJ. Reactions attributed to aspartame-containing products: 551 cases. J Appl Nutr. 1988; 40: 85-94.

Stegink LD, Filer LJ Jr, Bell EF, Ziegler EE, Tephly TR. Effect of repeated ingestion of aspartame-sweetened beverage on plasma amino acid, blood methanol, and blood formate concentrations in normal adults. Metabolism. 1989; 38:357-63.

Butchko HH, Stargel WW. Aspartame: scientific evaluation in the postmarketing period. Regul Toxicol Pharmacol. 2001; 34:221-33.

American Diabetes Association. Standards of medical care in diabetes-2006. Diabetes Care. 2006; 29 Suppl 1:S4-42.

Gougeon R, Spidel M, Lee K, Field CJ: Canadian Diabetes Association National Nutrition Committee Technical Review: Non-nutritive intense sweeteners in diabetes management. Can J Diabetes, 2004; 28: 385-399.

Lau DCW, Douketis JD, Morrison KM, Hramiak IM, Sharma AM, Ur E, et al. 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]. CMAJ. 2007; 176(8):S1-13.

Sandrou DK, Arvanitoyannis IS. Low-fat/calorie foods: current state and perspectives. Crit Rev Food Sci Nutr. 2000; 40(5):427-47.

Mortensen A. Sweeteners permitted in the European Union, Safety aspects. Scandinavian Journal of Food and Nutrition. 2006; 50:104-16.

Fagherazzi G, Vilier A, Saes Sartorelli D, Lajous M, Balkau B, Clavel-Chapelon F. Consumption of artificially and sugar-sweetened beverages and incident type 2 diabetes in the Etude Epidémiologique auprès des femmes de la Mutuelle Générale de l’Education Nationale-European Prospective Investigation into Cancer and Nutrition cohort. Am J Clin Nutr. 2013; 97(3):517-23.

Pretorius E, Bester J, Vermeulen N, Alummoottil S, Soma P, Buys AV, et al. Poorly controlled type 2 diabetes is accompanied by significant morphological and ultrastructural changes in both erythrocytes and in thrombin-generated fibrin: implications for diagnostics. Cardiovasc Diabetol. 2015; 14(1):30.

Bochenek M, Zalewski J, Sadowski J, Undas A. Type 2 diabetes as a modifier of fibrin clot properties in patients with coronary artery disease. J Thromb Thrombolysis. 2013; 35(2):264-70.

Buys AV, Van Rooy M-J, Soma P, Van Papendorp D, Lipinski B, Pretorius E. Changes in red blood cell membrane structure in type 2 diabetes: a scanning electron and atomic force microscopy study. Cardiovasc Diabetol. 2013; 12(1):25.

Dunn EJ, Philippou H, Ariëns RAS, Grant PJ. Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia. 2006; 49(5):1071-80.

Pretorius E, Oberholzer HM, van der Spuy WJ, Swanepoel AC, Soma P. Qualitative scanning electron microscopy analysis of fibrin networks and platelet abnormalities in diabetes. Blood Coagul Fibrinolysis. 2011; 22(6):463-7.

Swanepoel AC, Nielsen VG, Pretorius E. Viscoelasticity and ultrastructure in coagulation and inflammation: Two diverse techniques, one conclusion. Inflammation. 2015; 38(4):1707-26.

Bester J, Pretorius E. Effects of IL-1β, IL-6 and IL-8 on erythrocytes, platelets and clot viscoelasticity. Sci Rep. 2016; 6(1).

Borsey DQ, Prowse CV, Gray RS, Dawes J, James K, Elton RA, et al. Platelet and coagulation factors in proliferative diabetic retinopathy. J Clin Pathol. 1984; 37(6):659-64.

Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications. 2001; 15(1):44-54.

Roberts HJ. Aspartame-induced thrombocytopenia. South Med J. 2007; 100(5):543.

Frade LG, De La Calle H, Alava I, Navarro J, Creighton L, Gaffney P. Diabetes mellitus as a hypercoagulable state: its relationship with fibrin fragments and vascular damage. Thrombosis research. 1987; 47:533-40.

Hughes A, Mcverry B, Wilkinson L, Goldstone A, Lewis D, Bloom A. Diabetes, a hypercoagulable state? Haemostatic variables in newly diagnosed type 2 diabetic patients. Acta haematologica. 1983; 254-9.

Vinik AI, Erbas T, Park TS, Nolan R, Pittenger GL. Platelet dysfunction in type 2 diabetes. Diabetes Care. 2001;24(8):1476-85.

Pretorius E, Humphries P. Ultrastructural changes to rabbit fibrin and platelets due to aspartame. Ultrastruct Pathol. 2007; 31(2):77-83.

Page MJ, Bester J, Pretorius E. Interleukin-12 and its procoagulant effect on erythrocytes, platelets and fibrin (ogen): the lesser known side of inflammation. British journal of haematology. 2018; 180:110-7.

Marsh HC Jr, Meinwald YC, Lee S, Scheraga HA. Mechanism of action of thrombin on fibrinogen. Direct evidence for the involvement of phenylalanine at position P9. Biochemistry. 1982; 21(24):6167-71.

Marsh HC Jr, Meinwald YC, Thannhauser TW, Scheraga HA. Mechanism of action of thrombin on fibrinogen. Kinetic evidence for involvement of aspartic acid at position P10. Biochemistry. 1983; 22(18):4170-4.

Meinwald Y, Martinelli R, Van Nispen J, Scheraga H. Mechanism of action of thrombin on fibrinogen. Size of the A. alpha. fibrinogen-like peptide that contacts the active site of thrombin. Biochemistry. 1980; 19:3820-5.

Scheffler JE, Berliner LJ. Aspartame and aspartame derivatives effect human thrombin catalytic activity. Biophys Chem. 2004; 112(2-3):285-91.

Barradas MA, Gill DS, Fonseca VA, Mikhailidis DP, Dandona P. Intraplatelet serotonin in patients with diabetes mellitus and peripheral vascular disease. Eur J Clin Invest. 1988; 18(4):399-404.

Mohammad-Zadeh LF, Moses L, Gwaltney-Brant SM. Serotonin: a review. J Vet Pharmacol Ther. 2008; 31(3):187-99.

Stahl SM. The human platelet: a diagnostic and research tool for the study of biogenic amines in psychiatric and neurologic disorders. Archives of General Psychiatry. 1977; 34:509-16.

Stahl SM, Meltzer HY. A kinetic and pharmacologic analysis of 5-hydroxytryptamine transport by human platelets and platelet storage granules: comparison with central serotonergic neurons. J Pharmacol Exp Ther. 1978; 205(1):118-32.

Humphries P, Pretorius E, Naudé H. Direct and indirect cellular effects of aspartame on the brain. Eur J Clin Nutr. 2008; 62(4):451-62.

Erem C, Nuhoglu I, Yilmaz M, Kocak M, Demirel A, Ucuncu O, et al. Blood coagulation and fibrinolysis in patients with Cushing’s syndrome: Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels. J Endocrinol Invest. 2009; 32(2):169-74.

Känel R, Mills PJ, Fainman C, Dimsdale JE. Effects of psychological stress and psychiatric disorders on blood coagulation and fibrinolysis: a biobehavioral pathway to coronary artery disease? Psychosomatic Medicine. 2001; 63:531-44.

Van Zaane B, Nur E, Squizzato A, Dekkers OM, Twickler MTB, Fliers E, et al. Hypercoagulable state in Cushing’s syndrome: a systematic review. J Clin Endocrinol Metab. 2009; 94(8):2743-50.

Choudhary AK, Devi RS. Imbalance of the oxidant-antioxidant status by aspartame in the organs of immune system of Wistar albino rats. African Journal of Pharmacy and Pharmacology. 2014; 8:220-30.

Iyyaswamy A, Rathinasamy S. Effect of chronic exposure to aspartame on oxidative stress in brain discrete regions of albino rats. J Biosci. 2012; 37(4):679-88.

Chaouloff F. Physiopharmacological interactions between stress hormones and central serotonergic systems. Brain Res Rev. 1993; 18(1):1-32.

Pardridge WM, Mietus LJ. Transport of steroid hormones through the rat blood-brain barrier: primary role of albumin-bound hormone. Journal of Clinical Investigation. 1979; 64.

Keaney JF Jr, Loscalzo J. Diabetes, oxidative stress, and platelet activation. Circulation. 1999; 99(2):189-91.

Agamy N. Effects of the natural sweetener (stevia) and the artificial sweetener (aspartame) on some biochemical parameters in normal and alloxan-induced diabetic rats. N Biotechnol. 2009; 25:S12.

Arbind K, Devi R, Sundareswaran L. Role of antioxidant enzymes in oxidative stress and immune response evaluation of aspartame in blood cells of wistar albino rats. International Food Research Journal. 2014; 21:2263-72.

Choudhary AK, Devi RS. Serum biochemical responses under oxidative stress of aspartame in wistar albino rats. Asian Pac J Trop Dis. 2014; 4:S403-10.

Tsakiris S, Giannoulia-Karantana A, Simintzi I, Schulpis KH. The effect of aspartame metabolites on human erythrocyte membrane acetylcholinesterase activity. Pharmacol Res. 2006; 53(1):1-5.

Choudhary AK, Pretorius E. Revisiting the safety of aspartame. Nutr Rev. 2017; 75(9):718-30.

Dunn EJ, Ariëns RAS, Grant PJ. The influence of type 2 diabetes on fibrin structure and function. Diabetologia. 2005; 48(6):1198-206.


Download data is not yet available.


How to Cite
Choudhary, A. K. (2022). Aspartame and Platelets in Type II Diabetic Patients. European Journal of Medical and Health Sciences, 4(3), 52–56.